Clinical Trial Update: BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study [Phase 2]

View source ↗

Summary

A Phase 2 immunoMATCH pilot trial (BiCaZO) is evaluating cabozantinib in combination with nivolumab for advanced melanoma and head and neck squamous cell carcin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Melanoma
• Oropharyngeal Cancer

Drugs mentioned

• cabozantinib (cabozantinib)
• nivolumab (nivolumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 2 | Status: RECRUITING